Evidence map›Paper›PMID 23845738›Full record

ReviewThe international journal of biochemistry & cell biology2013

Mitochondrial dysfunction and sarcopenia of aging: from signaling pathways to clinical trials.

Emanuele Marzetti, Riccardo Calvani, Matteo Cesari, Thomas W Buford, Maria Lorenzi, Bradley J Behnke, Christiaan Leeuwenburgh

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The international journal of biochemistry & cell biology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02994901 (Cause and Importance of the Age-dependent Sarcopenia With a Blood Based Bioenergetics & Cytokine Profiling Approach), which is not on this map. Cited by 344 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
344citing papers in PubMed, 6 pooled it
16.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02994901 completednot on this mapstarted 2016, after this paper: background citation

Cause and Importance of the Age-dependent Sarcopenia With a Blood Based Bioenergetics & Cytokine Profiling Approach

TypeobservationalSponsorCharite University, Berlin, GermanyRan2016 to 2017Enrolled150ConditionsSarcopenia
3 · Its place in the literature

Who cites it

344 citing papers in PubMed, 6 syntheses or guidelines pooled it, 589 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Circulating Mediators of Apoptosis and Inflammation in Aging; Physical Exercise Intervention.International journal of environmental research and public health · 2021
    Trial
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review

284 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 4 countries.

Emanuele MarzettiDepartment of Geriatrics, Neurosciences and Orthopedics, Catholic University of the Sacred Heart School of Medicine, Rome 00168, Italy. emarzetti@live.com
Riccardo Calvani
Matteo Cesari
Thomas W Buford
Maria Lorenzi
Bradley J Behnke
Christiaan Leeuwenburgh
University of Florida · USUniversità Cattolica del Sacro Cuore · ITInserm · FRNational Research Council · IT

Funding

University of Florida Older Americans Independence Center (OAIC)P30AG028740 · NIA · UNIVERSITY OF FLORIDA · PI Peihua Qiu · 2007 to 2026
$22.8M
Apoptosis and Life-Long Caloric RestrictionR01AG021042 · NIA · UNIVERSITY OF FLORIDA · PI LEEUWENBURGH, CHRISTIAAN · 2003 to 2007
$1.7M
Mitophagy: target to improve liver function after ischemia/reperfusion injuryR01DK090115 · NIDDK · UNIVERSITY OF FLORIDA · PI KIM, JAE-SUNG, LEEUWENBURGH, CHRISTIAAN · 2012 to 2015
$1.3M
NIA NIH HHS 1P30AG028740NIA NIH HHS P30 AG028740NIA NIH HHS R01 AG021042NIA NIH HHS R01-AG21042NIDDK NIH HHS R01 DK090115NIDDK NIH HHS R01-DK090115-01A1
6 · The paper itself

Abstract

Sarcopenia, the age-related loss of muscle mass and function, imposes a dramatic burden on individuals and society. The development of preventive and therapeutic strategies against sarcopenia is therefore perceived as an urgent need by health professionals and has instigated intensive research on the pathophysiology of this syndrome. The pathogenesis of sarcopenia is multifaceted and encompasses lifestyle habits, systemic factors (e.g., chronic inflammation and hormonal alterations), local environment perturbations (e.g., vascular dysfunction), and intramuscular specific processes. In this scenario, derangements in skeletal myocyte mitochondrial function are recognized as major factors contributing to the age-dependent muscle degeneration. In this review, we summarize prominent findings and controversial issues on the contribution of specific mitochondrial processes - including oxidative stress, quality control mechanisms and apoptotic signaling - on the development of sarcopenia. Extramuscular alterations accompanying the aging process with a potential impact on myocyte mitochondrial function are also discussed. We conclude with presenting methodological and safety considerations for the design of clinical trials targeting mitochondrial dysfunction to treat sarcopenia. Special emphasis is placed on the importance of monitoring the effects of an intervention on muscle mitochondrial function and identifying the optimal target population for the trial. This article is part of a Directed Issue entitled: Molecular basis of muscle wasting.

Indexed as

AgedAgingAnimalsApoptosisHumansMitochondriaMitophagyOxidative StressRandomized Controlled Trials as TopicSarcopeniaSignal Transduction(31)P-NMR(31)P nuclear magnetic resonanceAIFAngIIangiotensin IIApoptosisapoptosis-inducing factorAtg proteinautophagy-related proteinB-cell leukemia-2Bcl-2Biomarkerschronic obstructive pulmonary diseaseCOPDCOXcross-sectional areaCSAcytochrome c oxidaseDrp1dynamin-related protein 1electron transport chainEndoGendonuclease Gendothelial nitric oxide synthaseeNOSETCFis1fission protein 1Forkhead box O3FoxO3Fusion and fissionGHgrowth hormoneIFMIGF-1inducible nitric oxide synthaseiNOSinsulin-like growth factor-1interfibrillar mitochondriaLAMP-2LC3lysosomal-associated membrane protein 2MfnMFRTAmicrotubule-associated protein 1 light chain 3mitochondrial DNAmitochondrial free radical theory of agingmitochondrial quality controlmitochondrial transcription factor AmitofusinMitophagyMQCmtDNAneuronal nitric oxide synthaseNF-κBnitric oxide synthasenNOSNOSnuclear factor κBOMMouter mitochondrial membraneoxidative phosphorylationOXPHOSperoxisome proliferator-activated receptor-γ coactivator-1αPGC-1αrandomized controlled trialRCTreactive oxygen speciesROSSDHSSMsubsarcolemmal mitochondriasuccinate dehydrogenaseTATFAMtibialis anteriorTNF-αtumor-necrosis factor αubiquitin–proteasome systemUPSVascular dysfunctionvastus lateralisVDRvitamin D receptorVL

Identifiers

PMID23845738
PMCPMC3759621
OpenAlexW2046119060

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.